早期子宫内膜癌不伴淋巴结清扫的腹腔镜与开腹手术后复发与生存:一项随机试验的长期结局
该多中心随机对照试验比较了不伴常规淋巴结清扫的腹腔镜全子宫切除术(TLH)与开腹全子宫切除术(TAH)治疗I期子宫内膜癌的5年生存结局。共279例女性接受手术,263例(94%)有随访数据。TLH组与TAH组的无病生存、总生存和疾病特异性生存均无显著差异,非劣效假设在10%显著性水平和0.20非劣效界值下被拒绝。
要点
- TLH组5年无病生存率为90.3%,TAH组为84.1%,aHR为0.69(95%CI 0.31-1.52)。
- TLH组5年总生存率为89.2%,TAH组为82.8%,aHR为0.60(95%CI 0.30-1.19)。
- TLH组5年疾病特异性生存率为95.0%,TAH组为89.8%,aHR为0.62(95%CI 0.23-1.70)。
核心结论
- TLH组与TAH组的疾病复发和5年生存率相当,且与伴淋巴结清扫的研究结果相当,支持将不伴淋巴结清扫的TLH作为早期低级别子宫内膜癌的主要治疗广泛应用。
研究设计与样本
- 多中心随机对照试验的随访研究,比较不伴常规淋巴结清扫的TLH与TAH治疗I期子宫内膜癌;2007年至2009年入组,按2:1随机分配至TLH或TAH;共279例女性接受手术,263例(94%)有随访数据。
主要发现
- TLH组(n=175)与TAH组(n=88)的5年无病生存率为90.3% vs 84.1%(aHR[复发] 0.69;95%CI 0.31-1.52),总生存率为89.2% vs 82.8%(aHR[死亡] 0.60;95%CI 0.30-1.19),疾病特异性生存率为95.0% vs 89.8%(aHR[死亡] 0.62;95%CI 0.23-1.70)。在10%显著性水平和0.20非劣效界值下,三种结局的非劣效假设均被拒绝。无穿刺孔或伤口转移,局部复发率相当。
关键数值与推荐
- 在10%显著性水平和0.20非劣效界值下,无病生存、总生存和疾病特异性生存的非劣效假设均被拒绝。
- TLH组5年无病生存率为90.3%,TAH组为84.1%,aHR为0.69(95%CI 0.31-1.52)。
- TLH组5年总生存率为89.2%,TAH组为82.8%,aHR为0.60(95%CI 0.30-1.19)。
- TLH组5年疾病特异性生存率为95.0%,TAH组为89.8%,aHR为0.62(95%CI 0.23-1.70)。
临床怎么用
- 作者认为,不伴淋巴结清扫的TLH可作为早期低级别子宫内膜癌的主要治疗广泛应用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Laparoscopic hysterectomy is accepted worldwide as the standard treatment option for early-stage endometrial cancer. However, there are limited data on long-term survival, particularly when no lymphadenectomy is performed. We compared the survival outcomes of total laparoscopic hysterectomy (TLH) and total abdominal hysterectomy (TAH), both without lymphadenectomy, for early-stage endometrial cancer up to 5 years postoperatively. METHODS: Follow-up of a multi-centre, randomised controlled trial comparing TLH and TAH, without routine lymphadenectomy, for women with stage I endometrial cancer. Enrolment was between 2007 and 2009 by 2:1 randomisation to TLH or TAH. Outcomes were disease-free survival (DFS), overall survival (OS), disease-specific survival (DSS), and primary site of recurrence. Multivariable Cox regression analyses were adjusted for age, stage, grade, and radiotherapy with adjusted hazard ratios (aHR) and 95% confidence intervals (95%CI) reported. To test for significance, non-inferiority margins were defined. RESULTS: In total, 279 women underwent a surgical procedure, of whom 263 (94%) had follow-up data. For the TLH (n = 175) and TAH (n = 88) groups, DFS (90.3% vs 84.1%; aHR[recurrence], 0.69; 95%CI, 0.31-1.52), OS (89.2% vs 82.8%; aHR[death], 0.60; 95%CI, 0.30-1.19), and DSS (95.0% vs 89.8%; aHR[death], 0.62; 95%CI, 0.23-1.70) were reported at 5 years. At a 10% significance level, and with a non-inferiority margin of 0.20, the null hypothesis of inferiority was rejected for all three outcomes. There were no port-site or wound metastases, and local recurrence rates were comparable. CONCLUSION: Disease recurrence and 5-year survival rates were comparable between the TLH and TAH groups and comparable to studies with lymphadenectomy, supporting the widespread use of TLH without lymphadenectomy as the primary treatment for early-stage, low-grade endometrial cancer.
引用
- Reijntjes B, van Suijlichem M, Woolderink JM, et al. Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: Long-term outcomes of a randomised trial. Gynecol Oncol. 2021. PMID: 34955237. doi:10.1016/j.ygyno.2021.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。